Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant Omnilink .018

This article was originally published in The Gray Sheet

Executive Summary

Biliary stent system gains FDA market go-ahead for treatment of malignant biliary obstructions. Cleared less than a month after agency sign-off on the firm's Rx Herculink Plus biliary stent system for the same indication, the Omnilink system is an enhanced version of Guidant's Megalink SDS biliary stent system and features added strength, lower profile and thinner (Xcelon) expansion balloon material (1"The Gray Sheet" April 23, 2001, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel